Brendan Classon

Title: Brendan Classon - Innovator in Domain Antibody Technology

Introduction

Brendan Classon is a prominent inventor based in Princeton, NJ, with a remarkable contribution to the field of biomedical innovation. He holds six patents, focusing primarily on domain antibody technologies that hold significant potential in therapeutic applications.

Latest Patents

Brendan's latest patents include compositions monovalent for CD28 binding and methods of use. These patents disclose domain antibodies that can monovalently bind CD28, a critical co-stimulatory receptor involved in T-cell activation. The domain antibodies designed by Brendan can inhibit CD28 activity without substantially agonizing it. Furthermore, his work encompasses methods for antagonizing CD80 and/or CD86 interactions with CD28, offering innovative approaches for treating diseases or disorders related to these interactions through the administration of domain antibodies.

Career Highlights

Throughout his career, Brendan has collaborated with reputable companies in the pharmaceutical sector. Notable among these are Domantis Limited and Bristol-Myers Squibb Company, where he has utilized his expertise to drive innovative research and development in therapeutic solutions.

Collaborations

In addition to his work in patenting new technologies, Brendan has collaborated with distinguished colleagues such as Murray McKinnon and Steven G. Nadler. These partnerships have furthered his innovations and contributed to significant advancements in the domain of immunology.

Conclusion

Brendan Classon's contributions to the field of domain antibody technology illustrate his role as a key innovator in biomedical science. With a well-established track record of patents and collaborations, he continues to pave the way for innovative therapeutic interventions. His work not only enhances our understanding of immune modulation but also holds promise for future treatments in various medical conditions.